We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ondine Biomedical Inc. | LSE:OBI | London | Ordinary Share | CA68234M2058 | COM SHS NPV (CDI) |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 8.50 | 3,332 | 07:31:35 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 8.00 | 9.00 | 8.50 | 8.50 | 8.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | CAD 1.2M | CAD -14.41M | CAD -0.0326 | -2.61 | 37.57M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 12:37:55 | O | 146 | 8.54 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 15/5/2025 | 14:30 | ALNC |  EARNINGS AND TRADING: Ondine widens loss as research expenses rise |
| 15/5/2025 | 07:00 | UK RNS | Ondine Biomedical Inc. 2024 Full Year Results and Annual Report |
| 12/5/2025 | 21:36 | ALNC | IN BRIEF: Ondine Biomedical joins CAN Health Network |
| 12/5/2025 | 07:00 | UK RNS | Ondine Biomedical Inc. Ondine Joins CAN Health Network |
| 09/5/2025 | 13:22 | ALNC | Ondine Biomedical names Alan Thomas as interim chief financial officer |
| 09/5/2025 | 07:00 | UK RNS | Ondine Biomedical Inc. Appointment of non-Board Interim CFO |
| 08/5/2025 | 07:00 | UK RNS | Ondine Biomedical Inc. Notice of Results and Investor Presentation |
| 09/4/2025 | 07:00 | UK RNS | Ondine Biomedical Inc. Economic study suggests c.£200 million UK savings |
| 08/4/2025 | 17:00 | UK RNS | Ondine Biomedical Inc. Replacement: Steriwave in first Swiss hospital |
| 08/4/2025 | 07:00 | UK RNS | Ondine Biomedical Inc. Steriwave in first Swiss hospital |
Ondine Biomedical (OBI) Share Charts1 Year Ondine Biomedical Chart |
|
1 Month Ondine Biomedical Chart |
Intraday Ondine Biomedical Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 20/5/2025 | 13:49 | OBI | 312 |
| 19/12/2024 | 08:48 | Steriwave is on track to be approved in the US in 2024 | 523 |
| 07/11/2024 | 07:52 | O B I | 678 |
| 31/8/2023 | 12:28 | Potential | 8 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 11:37:57 | 8.54 | 146 | 12.47 | O |
| 10:00:27 | 9.20 | 2,500 | 230.00 | UT |
| 07:34:07 | 9.00 | 434 | 39.06 | O |
| 07:34:05 | 8.00 | 252 | 20.16 | O |
| Top Posts |
|---|
Posted at 22/5/2025 09:20 by Ondine Biomedical Daily Update Ondine Biomedical Inc. is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker OBI. The last closing price for Ondine Biomedical was 8.50p.Ondine Biomedical currently has 442,038,143 shares in issue. The market capitalisation of Ondine Biomedical is £37,573,242. Ondine Biomedical has a price to earnings ratio (PE ratio) of -2.61. This morning OBI shares opened at 8.50p |
Posted at 15/5/2025 07:22 by bamboo2 15 May 2025ONDINE BIOMEDICAL INC. ("Ondine Biomedical", "Ondine" or the "Company") 2024 Full Year Results and Annual Report Ondine Biomedical Inc. (AIM: OBI), a global leader in light-activated antimicrobial technologies, announces its audited results for the year ended 31 December 2024. A complete version of the 2024 Annual Report and Accounts ("2024 Annual Report") can be found here: and is also being made available to shareholders on the Company's website at www.ondinebio.com/in All figures are expressed in Canadian Dollars, unless otherwise stated. The AGM will be held at 4:00 p.m. BST (8:00 a.m. Pacific Time) on 26 June 2025. The notice of AGM and a Proxy From will be published in due course and made available to shareholders. Carolyn Cross, CEO of Ondine Biomedical commented: "Building on years of success with a growing number of hospitals, we are focused on the foundational pillars that will drive sustainable growth and meaningful impact. The progress achieved commercially, clinically, and operationally in 2024 gives us strong confidence in our future plans and our ability to deliver significant value to our shareholders." 2024 Financial and Operational Highlights: · Revenue Growth and Commercial Expansion: Revenues increased by 70% to $2.0 million (2023: $1.2 million), driven by an 81% increase in hospital deployments and higher per-hospital revenue year-over-year despite a 40% reduction in sales and marketing spend. In the UK, Steriwave® became the first light-activated antimicrobial listed on NHS Supply Chain, enabling streamlined access for hospitals across England and Wales. · Strategic Distribution Partnership: Established a strategic distribution partnership with Mölnlycke Health Care, a world-leading MedTech company, to accelerate international reach for Steriwave into key markets, including the United Kingdom (UK), European Union (EU), and Middle East. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. · Margin Expansion: Gross margin improved to 64% (2023: 58%) as a result of operational efficiencies and the introduction of the enhanced Steriwave nasal illuminator, which is designed for enhanced performance, high-volume manufacturing, and improved margins. · Capital and Funding: Successfully raised $21.7 million net cash during 2024, with a further $5.7 million in strategic investment from a leading US healthcare entity shortly after the 2024 financial year-end, providing essential funding to initiate the Phase 3 clinical trial and support continued commercial expansion of Steriwave. · Clinical Progress: The pivotal US Phase 3 LANTERN clinical trial commenced with the first patient enrolled in December 2024. Early recruitment experiences informed efforts to optimize protocols, processing, and overall trial plans. Patient recruitment is actively progressing at 10 of the 14 planned HCA Healthcare hospitals, with additional site activations pending and further sites contemplated. With these measures, the Company anticipates last patient recruitment will be delayed by approximately one quarter. The Company agreed a clinical development program with the Royal Columbian Hospital Foundation, enabling acceleration of entry into the ICU market. The four-month ICU pilot trial began patient recruitment post-period, in March 2025. · R&D and Operating Expenses: Operating loss was $19.4 million (2023: $14.8 million), reflecting increased and upfront investment in clinical trials, FDA audit readiness, and operational infrastructure to support future growth. Live Presentation: Dr. Nicolas Loebel, President and Chief Technology Officer of the Company, will today provide a live presentation relating to the Full Year Results via Investor Meet Company at 16:30 BST (08:30 Pacific time). The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard, or at any time during the presentation. The recording and related slides will be made available after the presentation on the Company's website: www.ondinebio.com/in |
Posted at 08/4/2025 07:11 by bamboo2 08 April 2025ONDINE BIOMEDICAL INC. ("Ondine Biomedical", "Ondine", or the "Company") Switzerland's University Hospital Zurich undertakes independent research study on Steriwave for preoperative nasal decolonization Ondine Biomedical Inc. (LON: OBI) reports that University Hospital Zurich (USZ) has initiated an independent clinical study evaluating Steriwave®. This marks the first Swiss deployment of Ondine's nasal decolonization technology to combat surgical site infections (SSI). The study, titled "Preoperative Microbial Reduction of the Nasal Cavity with Antimicrobial Photodynamic Therapy (aPDT)," is led by Professor Dr. Harald Essig, Head of the Department of Cranio-Maxillo-Facia "Reducing post-surgical infections remains a top priority in Cranio-Maxillo-Facia Steriwave antimicrobial photodynamic therapy is a light-activated antimicrobial with ultra-fast efficacy that destroys a broad spectrum of pathogens, including antibiotic-resistant strains. This innovative technology is used to sanitize the nasal cavity, a primary reservoir for bacteria, viruses, and fungi that can lead to SSIs and hospital-acquired infections (HAI), particularly in high-risk surgical procedures. Unlike traditional approaches that rely on repeat doses of topical antibiotics and take days to take effect, Steriwave works immediately with a single, five-minute treatment, making it an ideal solution for preoperative nasal decolonization. The USZ study builds on extensive clinical use in Canada and the UK which have established that Steriwave enhances patient safety as well as combatting antimicrobial resistance. Carolyn Cross, CEO of Ondine Biomedical, stated: "Ondine Biomedical is proud to collaborate with the distinguished research team at University Hospital Zurich, where there is a strong and well-established history of researching aPDT. We appreciate their initiation of this study, and are confident the findings will further validate Steriwave's ability to rapidly and safely reduce pathogens associated with HAI. Deploying Steriwave at USZ is another important step in our mission to provide innovative, broad-spectrum solutions for infection prevention and to address the growing global threat of antimicrobial resistance." |
Posted at 19/3/2025 07:15 by bamboo2 Third trial underway.This is a pilot study in a new area of the hospital [ICU] for Ondine. ==================== 19 March 2025 ONDINE BIOMEDICAL INC. ("Ondine Biomedical", "Ondine", or the "Company") First patients recruited into Steriwave ICU pilot study and related Issue of Shares Ondine Biomedical Inc. (LON: OBI), a global leader in light-activated antimicrobial technologies, is pleased to announce that patient recruitment has commenced in an intensive care unit (ICU) pilot study at Royal Columbian Hospital (RCH) in New Westminster, British Columbia. Treating patients in intensive care units (ICUs) with Ondine's Steriwave® nasal photodisinfection technology would significantly expand the market opportunity for Steriwave. Infection prevention is a top priority in ICUs, where higher infection rates, critically ill patients, and bed capacity shortages create significant challenges. Unlike traditional antibiotics, Steriwave does not generate antimicrobial resistance. Already in use across Canada and in several UK NHS trusts before major surgery, this technology helps reduce the incidence of surgical site infections (SSIs) by decolonizing the nose-a major reservoir of infection-causing pathogens. The first patients were enrolled at RCH on 18 March 2025 for the four-month pilot involving approximately 400 ICU patients. This important study aims to evaluate the feasibility of conducting a larger safety and efficacy study of Steriwave in reducing hospital-acquired infections (HAIs) among critically ill patients in the ICU. HAIs, often caused by multidrug-resistant organisms, represent a growing challenge to healthcare systems worldwide. RCH, a level 1 trauma centre and one of the busiest in Canada, is the first to explore the use of Ondine's Steriwave nasal decolonization technology in ICUs. Conducted by ICU physician, Dr. Reynolds and his research team, this pilot study will evaluate how Steriwave can integrate into ICU infection control and workflow protocols and will make a preliminary assessment of its potential impact on infection rates, length of stay and patient mortality. This Investigator-Initiat Carolyn Cross, CEO of Ondine Biomedical, commented: "This trial represents a significant step forward in our mission to bring innovative infection prevention technologies to the most vulnerable patients. Partnering with Royal Columbian Hospital allows us to advance Steriwave's potential as a game-changing technology in ICU infection prevention practices." ICUs are often a hotbed for HAIs, with critically ill patients at heightened risk due to their compromised conditions and invasive procedures. In Canada alone, hundreds of thousands of ICU patients each year face a 12-13% risk of developing infections unrelated to their primary condition.[1] Antimicrobial resistance (AMR) has further complicated treatment, with resistance rates climbing to concerning levels. A landmark 2012 HCA Healthcare study involving nearly 75,000 ICU patients found that universal nasal decolonization using the antibiotic mupirocin reduced all-cause bloodstream infections by 44%.[2] However, reliance on mupirocin is increasingly risky-not only due to resistance rates as high as 80%[3] but also because its limited spectrum leaves patients vulnerable to pathogens it cannot address, underscoring the urgent need for innovative alternatives. Ondine's Steriwave is a non-invasive and painless treatment that uses a proprietary light-activated antimicrobial agent to destroy harmful pathogens, including bacteria, viruses, and fungi, in the nasal passages. The treatment is effective immediately, takes less than five minutes, and allows the normal nasal microbiome to recover swiftly. This groundbreaking approach offers a potentially life-saving solution for ICU patients, addressing a critical gap in infection prevention. Share Issuance Linked to Milestone Achievement As part of the clinical trial agreement, milestone payments to the trial site are payable in equity. Ondine Biomedical will issue shares equivalent to 25% of the agreed C$855,000 study cost for the second milestone of enrolling the first patient in the trial. The Company will issue 1,178,365 new ordinary shares of no par value in the capital of the Company ("Common Shares") at an issue price of 9.75 pence, reflecting the closing price of the Company's shares two business days preceding the first-patient-enrolm Admission, Settlement and Dealings Admission of the 1,178,365 new Common Shares will take place on or around 8.00 a.m. on 25 March 2025. The new Common Shares when issued, will be fully paid and will rank pari passu in all respects with the existing Common Shares in the Company, including the right to receive all dividends and other distributions declared, made or paid after the date of issue. Total Voting Rights Following Admission, the Company's issued and fully paid share capital will consist of 443,233,174 Common Shares, each carrying one voting right per Common Share. The Company does not hold any Common Shares in treasury. Therefore, the total number of Common Shares and voting rights in the Company following Admission will be 443,233,174. This figure may be used from the date of Admission until further notice by existing shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. All references to C$ in this announcement are to Canadian Dollars. This Announcement uses a C$:£ exchange rate of 1 : 0.5375 as at 16:30 (GMT) on 12 March 2025. |
Posted at 17/3/2025 08:20 by jailbird BambooDid you have follow advanced medical solutions ?They had half of amount of shares in issue but I am expecting OBi's revenues to be higher over time I remember buying them at 10p, and was a naive investor back then, sold at small profit .Once FDA was approved , the share price went up yearly reaching £3+ |
Posted at 27/1/2025 07:49 by bamboo2 HCA to invest US$4 million in OndineThis Announcement uses a US$:£ exchange rate of 1 : 0.808210 as at 16:30 (GMT) on 2 January 2025. Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company developing light-activated antimicrobial treatments, is pleased to announce that hInsight-NX, LLC, a subsidiary of HCA Healthcare, Inc., a leading healthcare provider in the United States, has committed to a US$4 million equity investment in the Company. The Company has agreed to issue 38,033,412 new common shares of no par value in the capital of the Company ("New Common Shares"), raising US$4 million (circa £3,232,840) at an issue price of approximately US$0.10517 per New Common Share (the "Private Placement"). The price of the subscription was determined by reference to the price the Company raised C$19.2 million in November 2024. The New Common Shares to be issued pursuant to the Private Placement will represent approximately 8.6041 per cent of the share capital of the Company as enlarged by the Private Placement. The shares will be issued non pre-emptively under the Company's existing authorities and are expected to be admitted to trading on AIM on 29 January 2025. The New Common Shares, when issued, will be fully paid and will rank pari passu in all respects with the existing common shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue. Use of Proceeds The proceeds from this investment will be used to support the Company's strategic objectives, including advancing key initiatives, to deliver long-term value. With the addition of this new investment, the Company expects its cash runway to extend into early Q4 2025. Total Voting Rights Following admission of the New Common Shares on 24 January 2025, the Company's issued and fully paid share capital will consist of 442,038,143 Common Shares, all of which carry one voting right per share. The Company does not hold any Common Shares in treasury. Therefore, the total number of Common Shares and voting rights in the Company at this date will be 442,038,143 Common Shares. This figure may be used from the date of Admission until further notice by Existing Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. Other Update As previously announced, Ondine entered into a private placement agreement with a Canadian private investor in September 2024. Due to the investor's unavoidable personal circumstances, settlement of the private placement continues to be delayed. The Company remains optimistic about the completion of this placement and will provide further updates as they become available. |
Posted at 14/11/2024 08:18 by bamboo2 Updated Result of FundraiseAll references to C$ in this announcement are to Canadian Dollars. This Announcement uses a C$:£ exchange rate of 1 : 0.5626 as at 16:30 (GMT) on 12 November 2024. Capitalized terms used in this announcement (this "Announcement") have the meanings given to them in the Proposed Fundraise announcement, unless the context provides otherwise. Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company, announces a further update to its Private Placement announced on 24 September 2024 and the Fundraising announced on 1 November 2024. The Company has no further clarity on the timing of the completion of the Private Placement but remains confident that this should complete in due course. Further updates will be provided when available. The Company announced on 1 November that certain of the directors of the Company have conditionally subscribed for, in aggregate, 2,479,035 Subscription Shares at the Issue Price. Since then, Carolyn Cross, CEO, has indicated her intention to subscribe for additional Subscription Shares and Nicolas Loebel, President and CTO, has indicated an intention to subscribe for Subscription Shares. In addition, the number of Subscription Shares to be issued to the relevant directors as set out in the 1 November announcement has been updated to take account of exchange rate variations. The Company can now confirm that Carolyn Cross, CEO, Robert Cross, husband to Carolyn Cross and Nicolas Loebel, President and CTO, intend to subscribe for a total of 19,372,003 Subscription Shares at the Issue Price (being 8.5 pence per Share). Furthermore, the Company has agreed with certain of its employees and vendors to settle payables in exchange for 1,816,670 shares in aggregate, also by way of subscription, thereby increasing the total number of Subscription Shares being subscribed for to 22,365,654 Subscription Shares. Therefore, the Subscription is now expected to raise gross proceeds of approximately C$3.6 million (c.£2.0 million). The Placing conditionally raised aggregate gross proceeds of approximately C$15.6 million (£8.8 million) pursuant to the placing of 103,403,318 Placing Shares with new and existing investors at the Issue Price. Therefore, the total gross proceeds from the Fundraising (being the Placing and the Subscription) is now expected to be c. C$19.2 million (c.£10.8 million), increased from c. C$16.2 million (£9.0 million announced on 1 November 2024. The estimated net proceeds are expected to be approximately C$18.1 million (c.£10.2 million), increased from c. C$15.1 million (c.£8.3 million). The Company confirms that admission and settlement of the 103,403,318 Placing Shares and 12,437,111 Subscription Shares amounting to c. C$17.7 million (c.£10.0 million) is now expected to take place on 18 November 2024 with the remaining 9,928,543 Subscription Shares amounting to C$1.5 million (c.£0.8 million), expected to be admitted to trading on AIM on or around 22 November 2024. The 125,768,972 New Common Shares, in aggregate to be issued pursuant to the Fundraising, represent approximately 45.2% per cent of the existing issued share capital of the Company. All shares issued pursuant to the Fundraising will be issued on a non pre-emptive basis under the Company's existing authorities. Increased Subscription & Related Party Transactions Certain of the directors of the Company intend to subscribe for, in aggregate, 20,548,984 Subscription Shares, to raise gross proceeds of approximately C$3.1 million (c.£1.75 million) for the Company, representing approximately 16.3 per cent of the New Common Shares from the completed Placing and the Subscription participations. Carolyn Cross and Robert Cross intend to subscribe for 18,710,100 New Common Shares. This is made up of: · A c.$0.9 million repayment of some of the outstanding balances due to Carolyn Cross, in exchange for 5,935,374 Subscription Shares. This is an increase of c.$0.7 million over the figure announced on 1 November 2024 ("Carolyn Cross' Enlarged Subscription"). · Conversion of C$130k (c. £73k) outstanding bonus due to Carolyn Cross into 860,474 Subscription Shares. · A subscription from Robert Cross amounting to 11,914,252 Subscription Shares for C$1.8 million (c.£1.0 million), to be paid in two tranches. The first tranche is for 1,985,709 Subscription Shares amounting to C$0.3 million (c.£0.17 million) ("Robert Cross' First Subscription"). The second tranche is for 9,928,543 Subscription Shares amounting to C$1.5 million (c.£0.84 million) ("Robert Cross' Second Subscription"). The number of New Common Shares, for which each of the Directors intend to subscribe, and their resulting shareholdings following the Admission of the Placing Shares and the Subscription Shares subscribed for to date, are set out below: Director Number of New Common Shares subscribed for in the Subscription Total Number of New Common Shares held on Admission % of issued share capital as enlarged by the completed Placing and Subscription2 Carolyn Cross1 18,710,100 155,864,029 38.58% Nicolas Loebel 661,903 3,513,991 0.87% Jean Duval 419,912 1,164,540 0.29% Junaid Bajwa 384,920 1,194,623 0.30% Margaret Shaw 197,186 214,328 0.05% Michael Farrar 174,963 485,228 0.12% 1 Existing beneficial holding includes 111,295,529 shares held by Carolyn Cross, including via holdings in 100% owned companies, and 25,858,400 shares held by Robert Cross, husband of Carolyn Cross. Following admission, the holdings will increase to 118,091,377 and 37,772,652 shares respectively. 2 Including issuance of 9,928,543 shares to Robert Cross to close on or about 22 November 2024. As previously announced, Carolyn Cross, CEO, provided loans, in aggregate, of C$1.245 million, to the Company (the "Loans") for additional working capital. Following the Subscription, the total outstanding loan balance is C$345,000, which may be repaid or converted to shares at 8.5 pence at a later date, subject to Board approval. The loan carries no interest and has no specific terms for repayment. The intended subscriptions by the Participating Directors will constitute related party transactions for the purposes of Rule 13 of the AIM Rules by virtue of such Persons being Directors of the Company. These Directors intend to participate at the same Issue Price as the Investors. Use of Proceeds and Further Funding The combined funds will be used to conduct the Company's US-based Phase 3 clinical trial for its Steriwave® nasal photodisinfection system, drive commercialization in approved markets, and support the Company's working capital needs, securing a cash runway into late Q2 2025. Together with the C$5 million (circa £2.8 million) Canadian Private Placement announced 24 September 2024, which will be settled in due course, the Company will have cash runway to early Q4 2025 and anticipated Phase 3 topline results In the event that the Company concludes the ongoing discussions with a major U.S. healthcare group regarding a potential investment of up to US$4 million (£3.1 million) the Company's expected cash runway would be into Q1 2027. Admission, Settlement and Dealings Admission of a total of 115,840,429 New Common Shares is expected to take place on or around 8.00 a.m. on 18 November 2024 with dealings on AIM in the commencing at the same time. Admission of the 9,928,543 shares under Robert Cross' Second Subscription is expected to take place on or around 8.00 a.m. on 22 November 2024 with dealings on AIM in the commencing at the same time. Admission is conditional upon, among other things, the Placing Agreement not having been terminated and becoming unconditional in all respects. The Placing Shares and Subscription Shares when issued, will be fully paid and will rank pari passu in all respects with the Existing Common Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue. |
Posted at 01/11/2024 18:04 by bamboo2 1 November 2024Ondine Biomedical Inc. ("OBI", "Ondine", or the "Company") Successful Fundraise, Upsized to C$16.2 million (£9.0m) Ondine secures funding for US Phase 3 clinical trial. Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company, is pleased to confirm, further to the announcement made earlier today (the "Launch Announcement"), the successful completion of the Placing and Subscription at the Issue Price of 8.5 pence per New Common Share. The Issue Price represents a premium of approximately 1.5 per cent. to the closing price of the Common Shares on 31 October 2024 of 8.375 pence. The total gross proceeds of the Fundraising have been upsized from the initial target of £8.5m, and are approximately C$16.2 million (£9.0 million) and the estimated net proceeds are expected to be approximately C$15.1 million (£8.3 million). The Placing has conditionally raised aggregate gross proceeds of approximately C$15.8 million (£8.8 million) pursuant to the placing of 103,403,318 Placing Shares with new and existing investors. The Subscription has raised further gross proceeds of approximately C$0.38 million (£0.21 million) pursuant to subscriptions received for 2,479,035 Subscription Shares. Carolyn Cross, CEO of Ondine, said: "With this key financing behind us, we are ready to embark on our key Phase 3 clinical trial in the USA and the first ICU trial in Canada. We are so grateful for the ongoing strong support of our shareholders, many representing top tier institutional investors and are very pleased to welcome significant new shareholders, including M&G Investment Management Limited, to the Company's share register." The 105,882,353 New Common Shares in aggregate to be issued pursuant to the Placing and the Subscription represent approximately 38 per cent. of the existing issued share capital of the Company. All shares issued pursuant to the Placing and Subscription will be issued non pre-emptively under the Company's existing authorities and are expected to be admitted to trading on AIM on or around 11 November 2024. RBC Europe Limited ("RBC"), Orana Corporate LLP ("Orana") and Oberon Capital, a trading name of Oberon Investments Limited, ("Oberon") acted as Joint Brokers to the Placing, and RBC and Oberon acted as Joint Bookrunners. The Placing was conducted following a market sounding by way of an accelerated bookbuild process. Related Party Transaction Certain of the directors of the Company have conditionally subscribed for, in aggregate, 2,479,035 Subscription Shares at the Issue Price, raising gross proceeds of approximately C$0.38 million (£0.21 million) for the Company, representing approximately 2.3 per cent of the New Common Shares from the completed Placing and the Subscription participations. The number of New Common Shares conditionally subscribed for by each of the Directors, and their resulting shareholdings following the Admission of the Placing Shares and the Subscription Shares subscribed for to date, are set out below: Director Number of New Common Shares subscribed for in the Subscription Total Number of New Common Shares held on Admission % of issued share capital as enlarged by the completed Placing and Subscription2 Carolyn Cross1 1,305,188 138,459,117 34.07% Jean Duval 420,923 1,164,540 0.29% Junaid Bajwa 385,846 1,194,623 0.29% Margaret Shaw 197,661 214,328 0.05% Michael Farrar 175,385 485,228 0.12% 1 Existing beneficial holding includes 111,295,529 shares held by Ms Carolyn Cross, including via holdings in 100% owned companies, and 25,858,400 shares held by Mr Robert Cross, husband of Ms Carolyn Cross. 2 Including issuance of 22,222,222 shares pursuant to capital raise announced on 24 September 2024, which will complete ahead of Admission As previously announced, Carolyn Cross, CEO, provided loans of, in aggregate, C$1.245 million, to the Company (the "Loans") for additional working capital. Ms Cross's participation in the Subscription is facilitated through C$0.2 million repayment in exchange for the 1,305,188 subscription shares shown above. Following the Subscription, the total outstanding loan balance is C$1.045 million, which may be repaid or converted to shares at 8.5 pence at a later date, subject to Board approval. The loan carries no interest and has no specific terms for repayment. The subscriptions by the Participating Directors constitute a related party transaction for the purposes of Rule 13 of the AIM Rules by virtue of such persons being directors of the Company and therefore related parties (the "Transaction"). The director independent of the Participating Directors, being Hon. Jean Charest, considers, having consulted with the Company's nominated adviser, that the terms of the participation by the Participating Directors, are fair and reasonable insofar as the Company's shareholders are concerned. Admission, Settlement and Dealings Admission of the Placing Shares and Subscription Shares is expected to take place on or before 8.00 a.m. on 11 November 2024 with dealings on AIM in the Placing Shares and the Subscription Shares commencing at the same time. Admission is conditional upon, among other things, the Placing Agreement not having been terminated and becoming unconditional in all respects. The Placing Shares and Subscription Shares when issued, will be fully paid and will rank pari passu in all respects with the Existing Common Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue. Total Voting Rights Following admission of the Placing Shares and Subscription Shares, in addition to admission of 22,222,222 shares in connection with the private placement announced on 24 September 2024, the Company's issued and fully paid share capital will consist of 406,340,334 Common Shares, all of which carry one voting right per share. The Company does not hold any Common Shares in treasury. Therefore, the total number of Common Shares and voting rights in the Company will be 406,340,334 after the admission of the Placing Shares and the Subscription Shares and the shares connected with the private placement announced on 24 September 2024. |
Posted at 01/11/2024 08:44 by bamboo2 1 November 2024Ondine Biomedical Inc. ("Ondine" or the "Company") Proposed Minimum £8.5 million (C$15.3m) Fundraise Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company, announces a proposed fundraising to raise not less than c.£8.5 million (C$15.3 million) from new and existing shareholders. The fundraising is being implemented by way of a proposed placing (the "Placing") and subscription (the "Subscription") (together, the "Fundraising"). The Fundraising involves the issuance of common shares without par value in the capital of the Company ("New Common Shares") at the price of 8.5 pence per New Common Share (the "Issue Price"). The majority of the Company's Directors (together the "Participating Directors") intend to participate in the Subscription for a total of c.£0.21 million (C$0.38 million) in gross proceeds forming part of the Fundraising, with such Subscription being conducted in accordance with applicable Canadian prospectus exemptions. The primary objective of the Fundraising is to provide the Company with sufficient capital to conduct the U.S. Phase 3 clinical study for its nasal photodisinfection system (branded as Steriwave® outside the U.S.). Finalized with regulatory input and in close collaboration with HCA Healthcare, Ondine's U.S. clinical trial partner, the circa 5,000-patient group-randomized crossover study is to be carried out at 14 HCA hospital sites and will compare standard-of-care infection prevention practices with and without nasal photodisinfection. The Company plans to recruit the first patient by the end of 2024, with the final patient expected mid-2025, and an early data readout anticipated in Autumn 2025. To support these goals, the Company seeks to raise a minimum of £8.5 million (C$15.3 million) from investors through the Fundraising. An additional C$5 million (c.£2.8 million) is anticipated from the equity raise via private placement which was announced to the market on 24 September 2024 and is due to settle by 8 November 2024 (the "Private Placement"). Combined, the Fundraising and Private Placement are projected to raise at least £11.3 million (C$20.4 million), providing sufficient funds to complete the Phase 3 trial through the final patient recruitment, drive commercialization in approved markets, and support the Company's working capital needs, securing a cash runway into early H2 2025. Additionally, the Company is engaged in discussions with a major U.S. healthcare group regarding a potential investment of up to US$4 million (£3.1 million). While the terms and structure of this investment are still under negotiation, the Company aims to finalize the arrangement by the end of 2024. If secured, this additional US$4 million investment would extend the cash runway to early Q2 2026, including anticipated Phase 3 topline results and NDA submission. If these negotiations do not yield an agreement, the Board will explore alternative funding options to extend the cash runway beyond early H2 2025. · The firm indications received in respect of Fundraising participations, as at the time of this announcement, are expected to result in a total new issuance of not less than 100,000,000 New Common Shares, representing approximately 36 per cent of the existing issued share capital of the Company. · The Issue Price represents a premium of approximately 1.5 per cent to the closing price on 31 October 2024 of 8.375 pence. · The final number and allocation of the Placing Shares will be determined by RBC Capital Markets, Orana Corporate LLP and Oberon Capital, a trading name of Oberon Investments Limited, in agreement with the Company and the result of the Placing will be announced as soon as practicable after the release of this announcement. · The planned issue of the New Common Shares pursuant to the Fundraising will take place on a non-pre-emptive basis. The Fundraising is not being underwritten. Intended Participation by Participating Directors in the Subscription Certain Directors of the Company have indicated their intention to subscribe for, in aggregate, 2,479,035 Subscription Shares at the Issue Price, raising gross proceeds of c.£0.21 million (C$0.38 million) for the Company. The participation in the Fundraising by the Participating Directors will be effected by entry into Subscription Agreements between the relevant Director and the Company. The participations in the Fundraising would, in aggregate, constitute a related party transaction under Rule 13 of the AIM Rules. Further disclosures will be made in a subsequent announcement in relation to these dealings. About the Placing and Subscription Pursuant to the Subscription, the Company will privately offer New Common Shares at the Issue Price ("Subscription Shares") to a limited number of entities and individuals both within and outside of the United Kingdom, under applicable regulatory exemptions as appropriate. The Placing, offering New Common Shares at the same Issue Price as the Subscription, is being undertaken by RBC Europe Limited ("RBC"), Orana Corporate LLP ("Orana") and Oberon Capital, a trading name of Oberon Investments Limited, ("Oberon") as Joint Brokers to the Placing, and RBC and Oberon as Joint Bookrunners, via an accelerated bookbuild process (the "Bookbuild"). The Bookbuild will be launched immediately following the release of this Announcement and is expected to close on 1 November 2024 (or such later time as may be agreed between the Joint Brokers, the Joint Bookrunners and the Company). The Placing is subject to the terms and conditions set out in Appendix I below. The Placing, which is conditional upon, inter alia, Admission becoming effective and the Placing Agreement (as defined below) becoming unconditional and not being terminated, and the Subscription are being carried out within the Company's existing statutory authority to issue shares on a non pre-emptive basis. The number of Placing Shares will be agreed by the Company in conjunction with the Joint Brokers and the Joint Bookrunners, and the result of the Placing will be confirmed by a further announcement released as soon as practicable thereafter. The timing of the closing of the Placing and the Result of Placing Announcement, final allocations and the total size of the Placing shall be determined at the absolute discretion of the Company, the Joint Brokers and the Joint Bookrunners. No aspect of the Fundraising is being underwritten. Expected Timetable of Principal Events 2024 Announcement of the Fundraising 1 November Announcement of result of the Fundraising 1 November Admission and commencement of dealings in the Placing Shares and Subscription Shares 11 November |
Posted at 10/5/2024 07:12 by z1co 10/05/2024:ONDINE BIOMEDICAL INC. ("Ondine Biomedical", "Ondine", or the "Company") ECDC report shows HAIs are increasing antibiotic use A third of microorganisms causing HAIs (healthcare-associat Ondine Biomedical (LON: OBI): A recent report from the European Centre for Disease Prevention and Control (ECDC) helps underscore the need for Ondine's light-activated antimicrobial technology, a much-needed innovation in the face of growing antibiotic resistance. The report reveals an alarming increase in antibiotic use and rising resistance and finds that 4.3 million patients in EU/EEA hospitals are affected by healthcare-associate The report, "Point prevalence survey of healthcare-associate ECDC Director Dr. Andrea Ammon said: "Healthcare-associat With the threat of antibiotic-resistant HAIs increasing year-on-year, there is a growing need for effective antimicrobials which do not generate resistance. Antimicrobial resistance (AMR) is responsible for 1.27 million deaths a year and is one of humanity's most urgent global public health threats.[1] Ondine's Steriwave light-activated antimicrobial technology is highly effective against all types of pathogens-viruses, bacteria and fungi-including those that cause HAIs, even those resistant to antibiotics. Steriwave is a broad-spectrum light-activated antimicrobial that uses a patented photosensitizer and associated red light to destroy pathogens in the nose. The nose is a major reservoir of bacteria, fungi, and viruses, which can spread from there to cause serious infections. Unlike traditional antibiotics, Steriwave is immediately effective with a single five-minute treatment and does not trigger AMR. In 2023, Ondine presented research at the 2023 International Consortium on Prevention & Infection Control (ICPIC) in Geneva, demonstrating that Steriwave was highly effective (>99.99% kills in 20 seconds) against both moderately drug-resistant (MDR) and extensively drug-resistant (XDR) bacteria.[2] Ondine's Steriwave technology is already used in the UK in the NHS and extensively in hospitals across Canada to prevent HAIs. In 2024, hospitals in Spain became the first in the EU to adopt this groundbreaking technology. The prestigious Hospital Universitario La Paz (HULP), a large tertiary hospital in Madrid with 1,308 beds, is one of three Spanish hospitals using Steriwave. According to the latest ECDC HAI surveillance report, the prevalence rate of HAIs in Spain is 8.2% compared to the median of 6.8%. Spain also had higher rates of antibiotic usage, with over 45% of patients with an HAI receiving antibiotics. More than 150,000 patients have been treated with Steriwave to date, and no serious side effects have been reported. |
Posted at 11/1/2024 15:00 by z1co Since you like replying when you're called a troll.A special educational post for you troll. I've bought these shares for the 12 to 18 months time frame just like i bought CSFS over a year ago when they were around 6p to 7p. Take a look at CSFS price is up 5 fold. OBI share price will no doubt rise over the short , medium and long term. For your education you just keep watching and posting on the forum. nb I have available funds to buy more if i decide to. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
.png){kind=logo}
